|Bid||15.15 x 800|
|Ask||15.32 x 4000|
|Day's range||15.12 - 15.53|
|52-week range||3.46 - 18.48|
|Beta (5Y monthly)||2.58|
|PE ratio (TTM)||N/A|
|Earnings date||03 Nov 2021 - 08 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||21.27|
Growth stocks can be a thing of beauty. The trick, if you will, is to suss out growth stocks that won't rot on the vine, so to speak. While both of these biotech stocks have more than doubled in value in the past three years, I believe each of these healthcare equities still has a lot of room to run in 2022 and beyond.
September's been a lousy month for biotech stocks with the Nasdaq Biotechnology Index down around 5.7% since the end of August. Rising interest rates are the main cause for concern, but that isn't a good reason to lose faith in this particular industry. You could sit around feeling sad about the September sell-off, or you could take advantage of some bargain stock opportunities.
BioCryst Pharmaceuticals discovers, develops, and markets novel small-molecule drugs to treat rare diseases. BioCryst already has a growing revenue source in Orladeyo. BioCryst stock has been soaring in response to Orladeyo's successful launch.